Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Association Between Plasma D Dimer in Adult CAP and Severity of Inflammatory Response and Survival

NCT07199530 · tracked via the Priya Life Science Egypt tracker
Phase
Observational
Started
2025-03-23
Last updated
2026-02-24

Condition(s) studied

D-dimer

Investigational drug(s) / intervention(s)

Blood Product

Blood Product: blood sample for D-dimer

Study summary

This observational study aims to investigate the association between elevated plasma D-dimer levels and the inflammatory response, as well as its impact on survival in adult patients with community-acquired pneumonia.

the study participants will be subjected to sampling for D-dimer and calculation of CURB-65 score. this aims to find the relation between them

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients who will be admitted to the Chest department, or coming to the outpatient clinic at Ain-Shams University Hospitals with CAP, and have the following inclusions: 1. age ≥18 years 2. diagnosis of CAP based on clinical symptoms, laboratory findings, and radiological evidence. Exclusion Criteria: * Patients with a history of coagulation disorders, cancer, or other chronic diseases, or refusal to participate. * patients who have any clinical or radiological signs suggesting COVID-19 pneumonia.

Primary outcome measure(s)

  • find the correlation between plasma D-dimer level and the severity of CAP — in 6 months
    measuring D-dimer level (\< 500 µg/L consider negative) on admission and correlating this with CAP severity.

Trial sites (1)

FacilityCityRegionStatus
Ain Shams University hospitals Cairo Egypt Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07199530 on ClinicalTrials.gov ↗ ← All trials in Egypt